Cargando…

Rationale for Tailoring an Alternative Oncology Trial Using a Novel Gallium-Based Nanocomplex: Mechanistic Insights and Preclinical Challenges

Introduction: In the fight against cancer, cisplatin is most widely used as a clinical mainstay for the chemotherapy of various human cancers. Meanwhile, its cytotoxic profile, as well as drug resistance, limits its widespread application. The goal of precision medicine is to tailor an optimized the...

Descripción completa

Detalles Bibliográficos
Autores principales: Mostafa, Nihal, Salem, Ahmed, Mansour, Somaya Z., El-Sonbaty, Sawsan M., Moawed, Fatma S. M., Kandil, Eman I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990695/
https://www.ncbi.nlm.nih.gov/pubmed/35382635
http://dx.doi.org/10.1177/15330338221085376
_version_ 1784683430580060160
author Mostafa, Nihal
Salem, Ahmed
Mansour, Somaya Z.
El-Sonbaty, Sawsan M.
Moawed, Fatma S. M.
Kandil, Eman I.
author_facet Mostafa, Nihal
Salem, Ahmed
Mansour, Somaya Z.
El-Sonbaty, Sawsan M.
Moawed, Fatma S. M.
Kandil, Eman I.
author_sort Mostafa, Nihal
collection PubMed
description Introduction: In the fight against cancer, cisplatin is most widely used as a clinical mainstay for the chemotherapy of various human cancers. Meanwhile, its cytotoxic profile, as well as drug resistance, limits its widespread application. The goal of precision medicine is to tailor an optimized therapeutic program based on the biology of the disease. Recently, nanotechnology has been demonstrated to be promising in this scenario. Objective: The current work provides a rationale for the design of an alternative oncology trial for the treatment of hepatocarcinogenesis using a novel eco-friendly nanocomplex, namely gallic acid-coated gallium nanoparticles. Moreover, the study tests whether the antineoplastic efficacy of gallic acid-coated gallium nanoparticles could be enhanced or not when it is administrated together with cisplatin. Methods: The work comprised a series of both in vitro and in vivo investigations. The in vivo therapeutic efficacy of such treatments, against diethylnitrosamine-induced hepatocarcinogenesis, was strictly evaluated by tracking target genes expressions, iron homeostasis, diverse biomarkers alterations, and lastly, routine paraclinical investigations were also assessed. Results: The in vitro biological evaluation of gallic acid-coated gallium nanoparticles in a HepG-2 cancer cell line established its superior cytotoxicity. Else more, the results of the in vivo experiment highlighted that gallic acid-coated gallium nanoparticles could diminish key hallmarks of cancer by ameliorating most of the investigated parameters. This was well-appreciated with the histopathological findings of the liver architectures of the treated groups. Conclusions: Our findings suggest that novel biogenic Ga-based nanocomplexes may potentially present new hope for the development of alternative liver cancer therapeutics, which should attract further scientific interest.
format Online
Article
Text
id pubmed-8990695
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-89906952022-04-09 Rationale for Tailoring an Alternative Oncology Trial Using a Novel Gallium-Based Nanocomplex: Mechanistic Insights and Preclinical Challenges Mostafa, Nihal Salem, Ahmed Mansour, Somaya Z. El-Sonbaty, Sawsan M. Moawed, Fatma S. M. Kandil, Eman I. Technol Cancer Res Treat Original Article Introduction: In the fight against cancer, cisplatin is most widely used as a clinical mainstay for the chemotherapy of various human cancers. Meanwhile, its cytotoxic profile, as well as drug resistance, limits its widespread application. The goal of precision medicine is to tailor an optimized therapeutic program based on the biology of the disease. Recently, nanotechnology has been demonstrated to be promising in this scenario. Objective: The current work provides a rationale for the design of an alternative oncology trial for the treatment of hepatocarcinogenesis using a novel eco-friendly nanocomplex, namely gallic acid-coated gallium nanoparticles. Moreover, the study tests whether the antineoplastic efficacy of gallic acid-coated gallium nanoparticles could be enhanced or not when it is administrated together with cisplatin. Methods: The work comprised a series of both in vitro and in vivo investigations. The in vivo therapeutic efficacy of such treatments, against diethylnitrosamine-induced hepatocarcinogenesis, was strictly evaluated by tracking target genes expressions, iron homeostasis, diverse biomarkers alterations, and lastly, routine paraclinical investigations were also assessed. Results: The in vitro biological evaluation of gallic acid-coated gallium nanoparticles in a HepG-2 cancer cell line established its superior cytotoxicity. Else more, the results of the in vivo experiment highlighted that gallic acid-coated gallium nanoparticles could diminish key hallmarks of cancer by ameliorating most of the investigated parameters. This was well-appreciated with the histopathological findings of the liver architectures of the treated groups. Conclusions: Our findings suggest that novel biogenic Ga-based nanocomplexes may potentially present new hope for the development of alternative liver cancer therapeutics, which should attract further scientific interest. SAGE Publications 2022-04-06 /pmc/articles/PMC8990695/ /pubmed/35382635 http://dx.doi.org/10.1177/15330338221085376 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Mostafa, Nihal
Salem, Ahmed
Mansour, Somaya Z.
El-Sonbaty, Sawsan M.
Moawed, Fatma S. M.
Kandil, Eman I.
Rationale for Tailoring an Alternative Oncology Trial Using a Novel Gallium-Based Nanocomplex: Mechanistic Insights and Preclinical Challenges
title Rationale for Tailoring an Alternative Oncology Trial Using a Novel Gallium-Based Nanocomplex: Mechanistic Insights and Preclinical Challenges
title_full Rationale for Tailoring an Alternative Oncology Trial Using a Novel Gallium-Based Nanocomplex: Mechanistic Insights and Preclinical Challenges
title_fullStr Rationale for Tailoring an Alternative Oncology Trial Using a Novel Gallium-Based Nanocomplex: Mechanistic Insights and Preclinical Challenges
title_full_unstemmed Rationale for Tailoring an Alternative Oncology Trial Using a Novel Gallium-Based Nanocomplex: Mechanistic Insights and Preclinical Challenges
title_short Rationale for Tailoring an Alternative Oncology Trial Using a Novel Gallium-Based Nanocomplex: Mechanistic Insights and Preclinical Challenges
title_sort rationale for tailoring an alternative oncology trial using a novel gallium-based nanocomplex: mechanistic insights and preclinical challenges
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990695/
https://www.ncbi.nlm.nih.gov/pubmed/35382635
http://dx.doi.org/10.1177/15330338221085376
work_keys_str_mv AT mostafanihal rationalefortailoringanalternativeoncologytrialusinganovelgalliumbasednanocomplexmechanisticinsightsandpreclinicalchallenges
AT salemahmed rationalefortailoringanalternativeoncologytrialusinganovelgalliumbasednanocomplexmechanisticinsightsandpreclinicalchallenges
AT mansoursomayaz rationalefortailoringanalternativeoncologytrialusinganovelgalliumbasednanocomplexmechanisticinsightsandpreclinicalchallenges
AT elsonbatysawsanm rationalefortailoringanalternativeoncologytrialusinganovelgalliumbasednanocomplexmechanisticinsightsandpreclinicalchallenges
AT moawedfatmasm rationalefortailoringanalternativeoncologytrialusinganovelgalliumbasednanocomplexmechanisticinsightsandpreclinicalchallenges
AT kandilemani rationalefortailoringanalternativeoncologytrialusinganovelgalliumbasednanocomplexmechanisticinsightsandpreclinicalchallenges